About Swedish Orphan Biovitrum Ltd

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families.

We have a diversified and growth-oriented commercial product portfolio. Key therapeutic areas are Inflammation and Genetics & Metabolism. Our Partner Product Portfolio areas includes amongst others Oncology, Surgery and Thalassemia. Our late stage pipeline includes three phase III programs with substantial potential. We have world-class capabilities in protein biochemistry and biologics manufacturing development - validated by leading industry partners. Global reachOur sales and marketing organization covers about 20 countries in Europe and a subsidiary in the US. We are also represented through partners in in the Middle East, Australia and New Zealand. Swedish Orphan Biovitrum develops, manufactures and sells medications for a number of diseases, with a special emphasis on four specialist areas: haemophilia, inflammation/autoimmune diseases, inherited metabolic diseases and oncology.

PatientsWe focus on medications for rare disease patients with a high unmet medical need. This category includes specialist and so-called orphan drugs, which are mainly prescribed by clinical specialists and aimed at small well-defined patient groups. These less common diseases are often neglected and inadequately treated which means that new medications can offer significant value for the patient and health care providers.